-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 26, 2021, LifeTech, a leading minimally invasive interventional medical device company for cardio-cerebrovascular and peripheral blood vessels, announced that its self-developed Xuper™ aortic stent graft system has obtained the EU CE certification
.
This innovative product is used for the hybrid surgical treatment of Stanford A-type aortic dissection.
It is the world's first commercialized multi-branch intraoperative stent graft system and will bring a new clinical treatment plan for the majority of patients
Aortic dissection is a cardiovascular disease that seriously threatens the life and health of patients
.
Among them, Stanford type A aortic dissection accounts for about 60%-70% of all aortic dissections.
It has the characteristics of high morbidity and high mortality.
Based on in-depth insights into clinical needs, LifeTech's Xuper™ intraoperative stent graft system came into being
.
The Xuper™ aortic stent graft is a unique "integrated" structure with branches on the main body, with three models of single-branch, double-branch and three-branch models
.
This new type of intraoperative aortic stent graft system combined with open surgery can speed up the operation while ensuring the quality of the operation, shorten the time of cardiopulmonary bypass and deep hypothermic circulatory arrest, effectively reduce intraoperative mortality and reduce surgery The occurrence of post-complications also reduces the difficulty of surgery and makes the learning curve shorter, which is conducive to its promotion and popularization on a global scale, thus saving more patients' precious lives
.
Xuper™ Intra-Aortic Stent Graft System is one of LifeTech's important innovative products in its aortic global treatment platform layout
.
The CE certification of the European Union this time provides a new, safe and effective surgical treatment plan for the majority of patients with Stanford A aortic dissection, and lays a foundation for further exploration and broadening of its indications, and will further consolidate LifeTech's in the aortic Comprehensive strength in the field of disease treatment
.
